Skip to content
Back to Investors
Techstart

Techstart

Venture Capital

Techstart Ventures is a venture capital fund manager operating in Scotland and Northern Ireland.


Recent investments

Pre-Seed
£910K

Lunar Ventures and Techstart Ventures co-led the pre-seed round for the computer vision start-up.

"I want to thank our team for the hard work they’ve put in to get us where we are today. Like most companies, we’ve hit a rough patch at the start of the pandemic and we wouldn’t have made it without each and every individual contribution."
— Paul Pop, CEO
Seed
£1.8M

Green Angel Syndicate led the investment round to accelerate international expansion and support team growth.

"This €2 million investment will allow us take our technology further into the European market and also enter the exciting North American market. We are planning to action our aggressive hiring plan over the coming months and grow our team significantly. This will initially focus on building our capacity to tackle major water management and sewer pollution issues through the hiring of software engineers, data scientists and drainage engineers, as well as expanding our marketing team to raise awareness of our products"
— Brian Moloney, CEO
Series A
£5.1M

The financing will support clinical trials, product development and team expansion as the business pursues international regulatory approvals.

"Our work in the US and the success of the trials we have run to date have demonstrated the potential of our technology and encouraged us to pursue other applications. With this financing and the backing of our investors we can accelerate our mission of delivering effective and non-invasive solutions for some of the most common and debilitating medical conditions."
— Jason McKeown, CEO
Series A
£1.1M

Par Equity led the Series A round to support technology development and commercial expansion.

"We are delighted to continue working with Par Equity who have been very supportive of our company and our vision. This investment will enable us to continue to develop and commercialise our cutting-edge technology that addresses a major unmet need in the development of novel therapies that can significantly reduce costs of care and improve patient outcomes for millions of people worldwide."
— Ronan Cunningham, CEO